Zobrazeno 1 - 10
of 66
pro vyhledávání: '"Toshihiro Wajima"'
Publikováno v:
Pharmacology Research & Perspectives, Vol 12, Iss 5, Pp n/a-n/a (2024)
Abstract When planning pediatric clinical trials, optimizing the sample size of neonates/infants is essential because it is difficult to enroll these subjects. In this simulation study, we evaluated the sample size of neonates/infants using a model
Externí odkaz:
https://doaj.org/article/14aaca4b0f53435dbcc0f44dcb2cd942
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 10, Iss 5, Pp 489-499 (2021)
Abstract Platelets are produced by hematopoietic stem cells via megakaryocytes in the bone marrow and play a critical role in hemostasis. The aim of this study was to develop a new platelet model based on the thrombopoiesis and platelet life‐cycle
Externí odkaz:
https://doaj.org/article/5069a63d6b644deb9ff99c959776ad84
Publikováno v:
The Journal of Clinical Pharmacology. 62:670-680
Cefiderocol is a siderophore cephalosporin for the treatment of infections caused by Gram-negative bacteria including carbapenem-resistant strains. The aim of this study was to develop an intrapulmonary pharmacokinetic model of cefiderocol and assess
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5dc6fcfcaff1d159cbf10eb5589030fa
https://doi.org/10.1002/jcph.1986
https://doi.org/10.1002/jcph.1986
Publikováno v:
Clinical Pharmacokinetics. 61:539-552
The need for continuous renal replacement therapy (CRRT) in critically ill patients with serious infections is associated with clinical failure, emergence of resistance, and excess mortality. These poor outcomes are attributable in large part to subt
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b3fe5fbce9504bf7a8895c3ac6c89fa4
https://doi.org/10.1007/s40262-021-01086-y
https://doi.org/10.1007/s40262-021-01086-y
Publikováno v:
Drug Metabolism and Pharmacokinetics. 51:100496
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ad845ede462c5779a9ca882afec27690
https://doi.org/10.1016/j.dmpk.2023.100496
https://doi.org/10.1016/j.dmpk.2023.100496
Autor:
Anju Menon, Simon Portsmouth, Yuko Matsunaga, Richard G. Wunderink, Keith A. Rodvold, David P. Nicolau, Toshihiro Wajima, Roger Echols, Takayuki Katsube
Publikováno v:
Journal of Antimicrobial Chemotherapy
ObjectivesLung penetration of cefiderocol, a novel siderophore cephalosporin approved for treatment of nosocomial pneumonia, has previously been evaluated in healthy subjects. This study assessed the intrapulmonary pharmacokinetic profile of cefidero
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3ed8c79503b27012e9ceb8a0e0d9bc88
https://doi.org/10.1093/jac/dkab280
https://doi.org/10.1093/jac/dkab280
Publikováno v:
Drug Metabolism and Pharmacokinetics. 35:548-554
Lisdexamfetamine dimesylate, a prodrug of d-amphetamine, has been approved for treatment of attention-deficit/hyperactivity disorder (ADHD). The purposes of this study were constructing a population pharmacokinetic model of d-amphetamine after dosing
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8872b94674ce8419f4b72ff1eb233ba6
https://doi.org/10.1016/j.dmpk.2020.08.005
https://doi.org/10.1016/j.dmpk.2020.08.005
Publikováno v:
Xenobiotica. 51:287-296
The human mass balance of lusutrombopag, an orally bioavailable thrombopoietin (TPO) receptor agonist, was characterised in seven healthy male subjects after a single oral dose of [14C]-lusutrombop...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2a724d3cdfb02fe222415abc0fb2f604
https://doi.org/10.1080/00498254.2020.1845416
https://doi.org/10.1080/00498254.2020.1845416
Publikováno v:
European Journal of Clinical Pharmacology
Purpose Drug-drug interaction (DDI) potentials of lusutrombopag, a thrombopoietin receptor agonist, on the activity of cytochrome P450 (CYP) 3A and of cyclosporine, which inhibits P-glycoprotein and breast cancer resistance protein, on lusutrombopag
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e2fda71dd1ed11251dec1c29d8d8293d
http://europepmc.org/articles/PMC7661413
http://europepmc.org/articles/PMC7661413
Publikováno v:
Drug Metabolism and Pharmacokinetics. 34:365-371
Guanfacine hydrochloride extended-release tablet (GXR) is approved for child and adolescent patients with attention-deficit/hyperactivity disorder (ADHD). The aims of this study were to develop a population pharmacokinetic model of guanfacine after a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6e48e864aa4610cd89c24cb85ad9d303
https://doi.org/10.1016/j.dmpk.2019.07.001
https://doi.org/10.1016/j.dmpk.2019.07.001